MedTrace Logo

Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D

NCT05140694 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 135

Last updated 2022-10-04

No results posted yet for this study

Summary

The co-administration of SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on glycemic control in subjects with type 2 diabetes mellitus and MAFLD better than empagliflozin or dulaglutide alone.

The SGLT2 inhibitor and GLP-1 receptor agonist would be safe and effective on fatty liver disease in subjects with type 2 diabetes mellitus and MAFLD.

Conditions

Interventions

DRUG

Empagliflozin

Empagliflozin 10 mg p.o. once daily (available to control over \~25mg)

DRUG

Dulaglutide

Dulaglutide 0.75mg s.c. once a week (available to control over \~1.5mg)

DRUG

Empagliflozin and Dulaglutide

Empagliflozin 10 mg p.o. once daily with Dulaglutide 0.75mg s.c. once weekly

Sponsors & Collaborators

  • Seoul National University Bundang Hospital

    lead OTHER

Principal Investigators

  • Soo Lim, MD, PhD · Seoul National University Bundang Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2024-06-30
Completion
2025-12-31

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05140694 on ClinicalTrials.gov